Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma

Glaucoma Clinical Trial

— CONDORE  

Official title:

Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04552964
• Other study ID #: CONDORE
• Status: Completed
• Phase: N/A
• Start date: September 25, 2020
• Est. completion date: April 27, 2021

Study information

• Verified date: July 2021
• Source: Laboratoires Thea
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Glaucoma is one of the most common chronic pathologies and affects several millions patients. Among these, many have a poorly controlled glaucoma, damaging vision and leading to blindness. One between principal reasons for poor glaucoma medication adherence is forgetfulness. To improve this issue, digital tools may benefit both ophthalmologists and patients by monitoring eye drop administration.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: April 27, 2021
• Est. primary completion date: April 27, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient > 18 years old, both genders

2. Diagnosed with glaucoma, with controlled IOP (<18mmHg)

3. Currently receiving a topical glaucoma treatment

4. Receiving a multitherapy a fixed combination of dorzolamide-timolol, preservative-free.

5. Patient willing to participate in the study.

6. Patient familiar with a smartphone and its applications

Exclusion Criteria:

1. Patient with any eye condition in addition to glaucoma requiring expected additional treatment

2. Patient with an ongoing or known history of ocular allergy and/or uveitis and/or viral infection and or ocular infection.

3. Patient who underwent intraocular surgery within the past 3 months or scheduled to undergo intraocular surgery within the next 3 months

4. Patient with best-correct visual acuity <20/70 in the better seeing eye

5. Patient whose drop administration is performed by someone else

6. Alcohol addiction and/or heavy smoker, according to the investigator's judgement.

7. Patient inability to understand the study procedures or to give informed consent.

8. Non-compliant patient (e.g., not willing to attend a visit; way of life interfering with compliance).

9. Participation in this study at the same time as in another clinical study.

10. Patient being institutionalized because of legal or regulatory order, inmate of psychiatric wards, prison or state institutions, or employee of the study sites or of the sponsor's company.

11. Patient not covered by the government health care scheme of the country in which he/she is living (if applicable).

12. Women of childbearing potential, pregnant or breastfeeding: Childbearing potential is defined as a woman who is not using a reliable method of contraception (oral contraceptive, intrauterine device, subcutaneous contraceptive implant, vaginal ring, patch) or is not surgically sterilized.

Related Conditions & MeSH terms

• Glaucoma

Intervention

Other:
• Single arm
Far Best Corrected Visual Acuity (BCVA) ; Intra-Ocular Pressure (IOP) assessment ; Fundus examination ; Automated visual field ; Slit lamp examination ; Pregnancy test ; Patient Satisfaction Questionnaire

Locations

Country	Name	City	State
France	Centre d'Ophtalmologie Blatin	Clermont-Ferrand

Sponsors (1)

Lead Sponsor	Collaborator
Laboratoires Thea

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Global patient satisfaction	Global patient satisfaction (Patient satisfaction questionnaire)	Week 9